Brought to you by 
Compugen, Merck Serono partner in inflammation
09 Dec 2008
Executive Summary
Israeli drug discovery company Compugen has chosen Merck Serono to help it continue development of CGEN855 (also referred to as CGEN855A and CGEN855B), a peptide in development for inflammatory diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Compugen, Merck Serono partner in inflammation
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice